PF-07220060 for Solid Cancers
(CDK4i Trial)
Trial Summary
What is the purpose of this trial?
This trial tests a new drug, PF-07220060, in patients with metastatic breast cancer. It aims to find the best dose and see if the drug helps stop cancer growth when used alone or with other treatments.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you must be refractory (not responding) to or intolerant of existing therapies known to provide clinical benefit for your condition.
Eligibility Criteria
This trial is for adults with advanced solid tumors, including specific breast and prostate cancers, who have not responded to existing therapies. Participants must have a certain level of physical fitness (ECOG PS 0 or 1) and adequate organ function. They should not have received cancer treatment within the last 2 weeks or be pregnant/breastfeeding.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Part 1A involves single escalating doses of PF-07220060 to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion.
Combination Therapy
Part 1B and Part 1C involve PF-07220060 administered in combination with endocrine therapies (letrozole and fulvestrant).
Dose Expansion
Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide.
Follow-up
Participants are monitored for safety and effectiveness after treatment.
Treatment Details
Interventions
- PF-07220060 (Other)